Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**ZFHX3 antisense RNA 1 (ZFHX3-AS1)** is a **long non-coding RNA (lncRNA)**, also known as **AC004943.2**. It is transcribed antisense to the ZFHX3 gene and is believed to function primarily as a *cis-acting regulatory RNA*, modulating the expression of the ZFHX3 gene, which encodes a large zinc finger homeodomain transcription factor with critical roles in neuronal development, tumor suppression, and cardiac function[1][3][4]. ZFHX3-AS1 itself does not encode a protein and is not recognized as a direct therapeutic target (such as a receptor, enzyme, or transporter)[1][3]. Its major biological significance lies in its potential regulatory effect on the ZFHX3 gene, indirectly affecting processes such as cellular differentiation and disease phenotypes where ZFHX3 is involved. No small-molecule drugs or biologics are currently known to target ZFHX3-AS1 directly; nor is it used as a clinical biomarker or associated with safety concerns[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZFHX3 antisense RNA 1 (ZFHX3-AS1).